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Nasopharyngeal cancers (NPC) are generally considered all those
tumours of epidermoid origin arising in the nasopharynx. They
constitute over 90% of tumours of this anatomical site. Basing 
on the degree of differentiation, the World Health Organization
(WHO) distinguished 3 different types of NPC: squamous cell
keratinizing carcinoma (type 1), non-keratinizing carcinoma (type
2) and undifferentiated carcinoma (type 3). According to the
Micheau classification (Micheau et al, 1981), NPC are divided
into two categories: squamous cell carcinoma and undifferentiated
carcinoma of nasopharyngeal type. Generally, the definition of
‘undifferentiated nasopharyngeal carcinoma’ (UNPC) is restricted
to the type 2 and 3 of the WHO classification or to the undifferen-
tiated carcinoma of nasopharyngeal type of the Micheau classifi-
cation. To distinguish the UNPC from the other epithelial tumours
of the nasopharynx is crucial since it widely differs from the others
in terms of epidemiology, clinical behaviour, pattern of spread and
sensitivity to radiation. 
The incidence of UNPC is very low in Western countries
(0.5–2/100 000/year) but it rises in the Mediterranean basin
countries (8–12/100000/year) and reaches the highest rates in the
south of China (25–50/100000/year) (Ho, 1978; Ho, 1982; Levine
and Conelly, 1985, pp 13–34; Li, 1985). Radiotherapy is the
historically accepted treatment for the UNPC. Unfortunately, most
of the studies with the largest series of patients include both early
and advanced stages, well differentiated and undifferentiated
tumours so that it is difficult to have clear data on radiation effi-
cacy in UNPC, stage by stage. Even with this limit, it is possible to
say that while in early stages radiation can give satisfactory long
term results (5-year survival: 75–95%) (Huang et al, 1985; Chatani
et al, 1986; Dexing et al, 1988), in locally advanced disease (T4
and/or N2–3), despite an overall immediate local control rate even
higher than 70%, the 5-year survival rate is 15–40% in most of the
studies (Huang, 1980; Chu et al, 1984; Zhang et al, 1987; Qin et al,
1988; Lee et al, 1992). Control of primary tumour and prevention
of distant dissemination are both major issues in locally advanced
disease. Local recurrence occurs in 15 to 54% of cases at 5 years,
mainly influenced by tumour stage and cranial nerve involvement,
as well as histological type (Mesic et al, 1981; Shwaab, 1983, 
pp 88–89; Sanguineti et al, 1997). The distant metastases rate is 20
to 35% at 5 years and reaches 60 to 80% for patients with N3
disease (Cvitkovic, 1991; Lee et al, 1992; Sanguineti et al, 1997). 
Experience with metastatic or recurring patients showed that
UNPC is a tumour sensitive to chemotherapy, particularly cisplatin.
Therefore, chemotherapy has been introduced also in patients with
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results over radiation alone. However, the role of chemotherapy in
a front line treatment of locally advanced disease is not yet
definitively assessed. In fact, at present, only one randomized
trial showed a statistically significant benefit in survival adding
chemotherapy to radiation (Al Sarraf et al, 1998). 
Here we report data from a prospective phase II trial testing the
feasibility and the activity in terms of complete response rates,
progression-free survival and overall survival of a treatment
programme including induction chemotherapy followed by an
alternating chemo-radiotherapy regimen. The aim of this strategy
was both to improve local control through a consolidated alter-
nating regimen that already showed this capacity in squamous cell
carcinoma (Merlano et al, 1992), and distant control through the
administration of more cycles of chemotherapy given at cytotoxic
doses even in the chemo-radiation phase. The induction regimen
chosen included cisplatin and epirubicin because, although suffi-
cient single agent phase II data is unavailable, the combination of
these two drugs gave high response rates and acceptable toxicity
(Licitra et al, 1994; Rahal et al, 1994; Oliveira et al, 1996; Chua et
al, 1998). 
MATERIALS AND METHODS 
Selection of patients 
Patients were elegible for the study if they had the following
features: histologically proven type 2 or 3 nasopharyngeal carcin-
oma according to the WHO classification; T4 and/or N2–3 disease
(stage IV) according to the UICC 1992 criteria; no previous treat-
ments; no distant metastases or other malignancies; age less than
71; performance status less than 2 (ECOG scale) (Miller et al,
1981); no major abnormalities of liver, heart, lung and bone
marrow function; informed consent. 
Pretreatment evaluation included physical and ENT examina-
tion, computerized tomography of the skull base and neck,
complete blood counts and blood chemistry profiles, chest X-ray,
liver echography and bone scan examination. 
Treatment 
The treatment protocol consisted of 3 courses of induction
chemotherapy followed by an alternating chemo-radiotherapy
programme. Each course of induction chemotherapy consisted of
cisplatin, 40 mg/m2/day, days 1 and 2, and epirubicin, 90 mg/m2,
day 1, every 3 weeks. The alternating programme generally started
4 weeks after the last induction course and consisted of 3 courses
of cisplatin, 20 mg/m2/day and fluorouracil 200 mg/m2/day for 4
consecutive days (weeks 1, 4, 7) alternated to 3 split courses of
radiation (weeks 2–3, 5–6, 8–9–10). Cisplatin was given during a
2-hour period of forced hydration. Fluorouracil was given as an
intravenous bolus dose at the end of cisplatin hydration. Anti-
emetic therapy consisted of dexametasone, 8 mg i.v. and trop-
isetron, 3 mg i.v., before each chemotherapy administration. 
In the induction phase patients recycled after 3 weeks if the
neutrophils count was ≥ 1500 cells µ l–1 and the platelets counts
was ≥ 90000 cells µ l–1, otherwise one more week of recovery was
planned. In case of grade IV neutropenia and/or thrombocyto-
penia, a 20% drugs reduction was done at the following course. In
the alternating programme if the neutrophil count was < 1500 cells
µ l–1 and the platelet count was < 90000 cells µ l–1 the chemotherapy
course was delayed for one week but the patient continued to be
treated with radiation in order to avoid breaks during the chemo-
radiation regimen. The routine administration of granulocyte
colony-stimulating factors was not allowed; their use was consid-
ered in single cases in order to reduce the risk of neutropenic fever
and to maintain the intervals between cycles within 4 weeks. In no
case was chemotherapy delivered concomitantly with radiation.
Temporary treatment interruptions were allowed only in cases of
grade IV mucositis. 
Radiotherapy consisted of 70 gray delivered as daily single
doses of 2 gray, 5 times a week during weeks 2–3, 5–6 and
8–9–10. For the initial 50 gray, two lateral and parallel opposed
photon (cobalt or 6 MV) customized fields were used to treat the
primary site and upper-mid neck nodes. The dose was specified
and calculated at midplane along the central axis for lateral
opposed beams. 50 gray were prescribed to electively treat neck
regions as well. The lower neck–supraclavicular regions were
treated with an appositional, anteroposterior field, with the dose
prescribed at the depth of 3 cm. Areas of initial disease on both
tumour and/or node sites were boosted to 60 gray regardless of
response to induction chemotherapy. Areas of residual primary
and/or nodal, postinduction chemotherapy disease were treated to
70 gray. This was generally done by the usual shrinking field tech-
nique. During this phase, higher energy (15–18 MV photons) were
used to treat the primary site. However, for 12 T4 patients, a
conformal 3D approach with multiple co-planar fields was
attempted. The dose to the spinal cord was to be limited to 50 gray. 
Evaluation of response and toxicity 
The response to treatment was assessed at the end of induction
chemotherapy and 2 months after the end of the alternating
programme through an ENT evaluation and a computerized
tomography of the skull base and neck. Complete response (CR)
was defined as the complete disappearance of all lesions; partial
response (PR) was defined as a 50% or more reduction of the sum
of the products of the two longest diameters of all lesions.
Treatment failure was indicated by stable disease (SD), defined as
a decrease of less than 50% or an increase of less than 25%;
disease progression (PD), defined as an increase of more than
25%; early death (ED), defined as any death occurring before the
end of treatment for tumour and treatment due to unrelated causes. 
Toxicities were evaluated according to the WHO scale (Miller
et al, 1981) and recorded as the worst grade experienced by
patients during the treatment. 
Patients underwent a follow-up programme including a monthly
physical examination (in the first year, then every 3 months), an
ecography of the neck every 3 months (at least in the first year), a
CT scan of the skull base and neck and a chest X-ray every 6
months and a bone scan examination every year. 
Progression-free survival and overall survival 
Progression-free survival was computed from the time of treat-
ment beginning until that of disease progression at any site
including distant metastasis or second primary tumours. Patients
who died without evidence of disease progression were considered
to have had progressive disease at the time of death. Overall
survival was computed from the time of treatment beginning until
the time of the last follow-up or death. All patients were included
in the above analyses. 
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Actuarial survival and progression-free survival analyses were
carried out according to the Kaplan-Meier method (Kaplan and
Meier, 1958). 
RESULTS 
Between May 1995 and June 1999, 30 consecutive patients (18
males and 12 females) entered this phase II prospective study. The
median age was 50 (range: 21–70) and the median performance
status was 0 (range: 0–1). 9 patients (30%) had a WHO type 2 and
21 patients (70%) type 3 histology. Tumour and nodal extensions
are listed in Table 1. 57 percent of the patients had T4 and 77%
N2–3 disease; 33% of the patients had both T4 and N2–3 lesions. 
All the patients completed the treatment programme and are
fully evaluable for toxicity and response. The compliance to the
treatment was good (Table 2). 28 patients (93%) received all the 6
courses of chemotherapy planned in the 2 phases of the treatment. 
Induction phase 
All the patients but one (97%) received the 3 planned courses of
chemotherapy. One patient stopped the neoadjuvant chemotherapy
after the second course because of grade III diarrhoea lasting more
than 5 days. A single episode of grade III stomatitis was observed
in one patient after the third course. A weight loss between 5% and
10% was recorded in 23% of the patients. Excluding alopecia and
vomiting, other toxicities were mild to moderate (Table 3). We
observed 7 CRs (23.3%), 19 PRs (63.3%), 4 SDs (13.3%) in the
nasopharynx and 3 CRs (12%), 20 PRs (83%) and 1 SD (4%) in
the neck. Overall, 3 patients reached a CR (10%), 25 patients a PR
(83.3%) and 2 patients had a SD (6.7%). 
Alternating phase 
The chemo-radiation treatment was delivered on an out-patient
basis in any case. All patients but one (97%) received the planned
number of chemotherapy courses. One patient received only the
first course of cisplatin and fluorouracil due to a persistent increase
of the serum creatinine values (ranging between 2.5 and 3.0 mg
dl–1). All the patients received the planned radiation dose. The dose
of radiation administered on the primary tumour was 70 gray in
27 patients. 3 patients with T1–2 lesions in CR after induction
chemotherapy received 60 gray. The dose of radiation adminis-
tered on the neck was 70 gray in 23 patients. 3 patients in CR after
induction chemotherapy received 60 gray and 4 patients without
nodal involvement at the time of diagnosis had 50 gray. A treat-
ment delay of one week was needed in 5 patients (16.7%) and of 2
weeks in 2 (6.7%). The reason for the delays was correlated to the
severity of local toxicity in 4 patients. 
The main toxicity (Table 3) was local: 33.3% of the patients
suffered from grade III–IV mucositis and despite supportive care
including tube feeding and intravenous hydration given in most of
the cases, these patients had a weight loss ranging between 10%
and 15%. The median time to recovery to normal enteral nutrition
for these patients was 4 weeks (range 1–8 weeks) from the end of
the treatment. Grades II–III dermatitis was observed in 16.7%
of the patients. Haematological toxicity was generally mild to
moderate: 16.7% of the patient had grade III neutropenia and 10%
grade III–IV thrombocytopenia. 
The clinical and radiological evaluation performed 2 months
after the end of the treatment programme showed 26 CRs (86.7%)
and 4 PRs (13.3%). At the time of the present analysis (June 2000)
the median follow-up calculated from the end of the treatment
programme was 31 months (range 8–56). 9 patients had a disease
progression and 1 patient developed an adenocarcinoma of the
lung (Table 4). The rates of locoregional progressions and distant
metastases were 13.3% and 20%, respectively. 
Two out of 3 patients who developed locoregional progression
only had a WHO type 2 histology, while 5/6 patients who devel-
oped distant metastases had a WHO type 3 histology. Distant
metastates were detected at 7, 9, 9, 15, 22 and 58 months from the
treatment beginning. 
One patient out of those progressed refused any further treat-
ment. One patient was reirradiated for a local progression and again
had a CR lasting 24 months. 5 patients had a taxanes-based second-
line chemotherapy and 3 of them partially responded. Two patients
Table 1 Tumour and node staging 
T1 T2 T3 T4 Total 
N0 – – – 4 4 
N1 – – – 3 3 
N2a 1 2 – 2 5 
N2b – 6 – 4 10 
N2c – 1 2 3 6 
N3 1 – – 1 2 
Total 2 9 2 17 
Table 2 Toxicity 
Induction chemotherapy Chemo-radiotherapy 
WHO Grade I (%) II (%) III (%) IV (%) I (%) II (%) III (%) IV (%) 
Leucopenia 2 (6.7) 3 (10) 3 (10) – 3 (10) 11 (36.7) 5 (16.7) – 
Thrombocytopenia – – – – 4 (13.3) 2 (6.7) 2 (6.7) 1 (3.3) 
Anaemia 6 (20) 3 (10) – – 11 (36.7) 6 (20) 1 (3.3) – 
Nausea/vomiting 2 (6.7) 14 (46.7) 8 (26.7) – 7 (23.3) 12 (40) 4 (13.3) – 
Mucositis 5 (16.7) 1 (3.3) 1 (3.3) – 3 (10) 14 (46.7) 8 (26.7) 2 (6.7) 
Alopecia – 10 (33.3) 20 (66.6) – – – – – 
Diarrhoea – – 1 (3.3) – – – 1 (3.3) – 
Fever – 3 (10) – – – 1 (3.3) – – 
Renal – – – – 1 (3.3) – – – 
Neurotoxicity – – – – 9 (30) 2 (6.7) 1 (3.3) – 
Dermatitis – – – – 4 (13.3) 2 (6.7) 3 (10) – 1440 M Benasso et al
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with liver metastases underwent a high-dose chemotherapy
programme with peripheral stem cell support. They both reached a
PR and progressed after 2 and 4 months respectively. 
The 2-year actuarial progression-free survival and overall
survival rates were 79% and 88%. The 3-year actuarial
progression-free survival and overall survival rates were 64% and
83% (Figure 1). 
DISCUSSION 
Radiotherapy alone has been considered up to now the standard
treatment of locally advanced UNPC. Due to the low incidence of
this disease only a few randomized trials investigating the role of
chemotherapy in a front line treatment are available. The first
study published (Rossi et al, 1988) failed to demonstrate any
benefit for the addition of adjuvant chemotherapy after radiation.
However, in this study the chemotherapy combination did not
include cisplatin, which is the most active drug in this disease. A
smaller trial (Chan et al, 1995) tested an experimental treatment in
which chemotherapy was given before and after radiation. Also in
this case no benefit was observed over radiotherapy alone. Two
studies investigated the role of chemotherapy administered only
before radiation. A statistically significant advantage in pro-
gression-free survival but not in overall survival was reported in
one (VUMCA, 1996; El Guedari, 1998). No statistically signifi-
cant benefit was observed in the other one (Chua et al, 1998).
Concomitant chemo-radiotherapy followed by adjuvant chemo-
therapy was the experimental treatment in the Intergroup trial (Al
Sarraf et al, 1998). This strategy led to a statistically significant
improvement of progression-free survival and overall survival.
The incidence of distant metastases was decreased from 61% to
23% and that of locoregional failures from 43% to 15% at a
median follow up of 2.7 years. What we learned from these trials
can be summarized as follows. The only therapeutical approach
showing a clear benefit over standard radiation is, at present, that
including concomitant chemo-radiotherapy. Therefore, by now,
concomitant chemoradiation should be seriously considered as a
part of any treatment programme for locally advanced UNPC. 
The role of a sequential approach including induction and/or
adjuvant chemotherapy and standard radiotherapy is still debated.
If a benefit does exist it is probably small. 
The addition of neoadjuvant or adjuvant chemotherapy to a
concomitant chemoradiation programme like in the intergroup
trial, could be a fruitful strategy in the attempt to reduce further the
incidence of distant metastases and possibly locoregional relapses. 
The main limit to adjuvant chemotherapy in head and neck
cancer is the low patient compliance. In fact, the proportion of
patients not receiving an adequate number of adjuvant chemo-
therapy courses after a locoregional treatment, for any cause, is
generally high. On the contrary, compliance to induction chemo-
therapy is generally better. Moreover, an active induction regimen
may be able both to reduce the tumour mass before the local treat-
ment and to eradicate early systemic micrometastases. For these
reasons in our trial we choose to give chemotherapy before the
alternating regimen. To the best of our knowledge this is the first
experience reported with a similar approach. 
The main finding from the present study is regarding the feasi-
bility of this combined treatment. Despite the duration of the
whole programme being very long (20 weeks) if compared to that
of a radiation alone or a concomitant chemo-radiation approach 
(7 weeks), the patients compliance was notable. 
None interrupted the treatment early and 93% of the patients
received all the 6 courses of chemotherapy planned in the 2 phases
of the treatment. Moreover, the relative dose intensity of the drugs
exceeded 90% in 87% of the patients both in the induction and in
the alternating phase. These data compare favourably to those
Table 3 Compliance with treatment 
No. of patients % 
Overall no. of CT courses 
6 28 93.3 
5 1 3.3 
4 1 3.3 
Neoadjuvant CT (RDI) 
100 % 23 76.7 
>90 % 3 10 
≤ 90 % 4 13.3 
Alternating CT (RDI) 
100 % 20 66.7 
>90 % 6 20 
≤ 90 % 4 13.3 
RT dose (T) 
70 Gy 27 90 
60 Gy 3 10 
RT dose (N)
70 GY 23 76.7
60 Gy 3 10 
50 Gy 4 13.3 
CT = chemotherapy; RT = radiotherapy; RDI = relative dose intensity; 
T = tumour; N = nodes 
Table 4 Incidence and site of progression 
No. of patients % 
Local only 2 6.7 
Local and nodal 1 3.3 
Nodal and distant 1 3.3 
Distant only 5 16.7 
II primary 1 3.3 
10 33.3 
Liver 3 10 
Bone 4 13.3 












Figure 1 Overall survival (OS) and progression free survival (PFS)reported by others with adjuvant chemotherapy. 20% of the
patients never started or stopped adjuvant chemotherapy early in
the Rossi trial; 46% of the patients did not receive postradiation
chemotherapy as planned in the Chan trial; one third of the patients
never started and only one half had the planned adjuvant chemo-
therapy in the Intergroup study. 
Our programme had acceptable toxicity. Haematological side
effects were generally mild to moderate and the incidence of
severe mucositis (33%) during the alternating programme was
similar to that expected with radiation alone. These data are in line
with those we reported previously with alternating chemo-
radiation (Merlano et al, 1992). Another promising finding from
our study is regarding the activity. 87% of CRs at the end of the
whole treatment programme, 3-year progression-free survival rate
of 64% and overall survival rate of 83% compare favourably to
those reported in the literature, considering that only patients with
stage IV disease were included in this trial and that most of the
events generally occur during the first 3 years following treatment,
and before 18 months in a high proportion of cases (Hoppe et al,
1976; Vikram et al, 1985; Chen et al, 1989; Qin et al, 1988). In
fact, it should be considered that 5-year survival of patients with
stage III–IV UNPC reported in uncontrolled studies with radiation
alone is 15–40% (Huang, 1980; Chu et al, 1984; Zhang et al, 1987;
Qin et al, 1988; Lee, 1992) and 3-year progression-free survival
and overall survival rates reported in the radiation alone arm of the
2 randomized trials whose median follow-up is similar to that of
our study (30–31 months) are 24% and 47% (Al Sarraf et al, 1998)
and 42% and 71% (Chua et al, 1998). Even the frequencies of
distant metastases and locoregional progressions seem to be lower
in our study (20% and 13%, respectively) than in the Intergroup
trial (61% and 43%) and in the Chua trial (25% and 30%) with
radiation alone. It must be stressed, however, that in those trials
also patients with stage III disease (according to the Ho’s stage in
the Chua trial) were enrolled and that in the Intergroup trial 25% of
the patients had a WHO I histology, that means a lower metasta-
sizing behaviour. 
In conclusion, induction chemotherapy followed by an alter-
nating chemo-radiotherapy regimen as we did in our trial showed
an acceptable toxicity and an optimal patient compliance. Results
in terms of activity seem to confirm the superiority of chemoradia-
tion over radiotherapy alone shown by the Intergroup trial. If addi-
tional effective chemotherapy is needed to further improve the
results of the concomitant treatment, the administration of chemo-
therapy before the concomitant treatment is in our opinion the
more feasible option. However, a randomized trial is needed to test
this hypothesis. 
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